MarketPeel
Insider Trading Intelligence
MA

Matthias Alder

GANX
CHIEF EXECUTIVE OFFICER · GAIN THERAPEUTICS, INC. · CIK 0001370820
FILING MIX · LIFETIME60%/40%
BUYS
15
SELLS
10
TOTAL VALUE
$1.20M
COMPANIES
1
ACTIVE SINCE
Dec 2021
HOLDINGS NOW
8,250
AVG SELL PX
$3.67
TRADE KIND
SHOWING 25 / 25
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizons
Forward-return performance of every backtestable P/S trade by Matthias Alder, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+0.00%+9.20%+1.93%+7.27%+7.27%
14d2+50.00%+22.40%+1.22%+21.19%+21.19%
30d2+0.00%+41.01%+2.29%+38.71%+38.71%
60d2+0.00%+80.50%+6.51%+74.00%+74.00%
90d2+0.00%+78.65%+11.07%+67.58%+67.58%
180d2+100.00%-25.79%+16.27%-42.05%-42.05%
1y2+100.00%-33.28%+30.55%-63.83%-63.83%
2y2+0.00%+33.89%+49.45%-15.56%-15.56%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
GANX · 8,250 shares · as of Mar 26, 2024
092,500185,000277,500370,000202220232024SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
FLOW · 15 buys / 10 sellsCOVERAGE · 10 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
82526,588Mar 26, 2024Mar 28, 2024View →
GANX
GAIN THERAPEUTICS, INC.
SALE
Chief Executive Officer
6376,376Mar 26, 2024Mar 28, 2024View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
63727,225Mar 26, 2024Mar 28, 2024View →
GANX
GAIN THERAPEUTICS, INC.
SALE
Chief Executive Officer
6,085$4.06$24.7K21,140Mar 26, 2024Mar 28, 2024View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
18,75025,763Mar 26, 2024Mar 28, 2024View →
GANX
GAIN THERAPEUTICS, INC.
SALE
Chief Executive Officer
18,75056,250Mar 26, 2024Mar 28, 2024View →
GANX
GAIN THERAPEUTICS, INC.
SALE
Chief Executive Officer
8258,250Mar 26, 2024Mar 28, 2024View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
370,000370,000Mar 21, 2024Mar 25, 2024View →
GANX
GAIN THERAPEUTICS, INC.
SALE
Chief Executive Officer
206$2.46$5075,286Dec 21, 2023Dec 22, 2023View →
GANX
GAIN THERAPEUTICS, INC.
SALE
Chief Executive Officer
6377,013Dec 20, 2023Dec 22, 2023View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
6375,492Dec 20, 2023Dec 22, 2023View →
GANX
GAIN THERAPEUTICS, INC.
SALE
Chief Executive Officer
1,820$2.50$4.5K4,855Dec 7, 2023Dec 14, 2023View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
8256,675Oct 1, 2023Oct 3, 2023View →
GANX
GAIN THERAPEUTICS, INC.
SALE
Chief Executive Officer
8259,075Oct 1, 2023Oct 3, 2023View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
2,5505,850Sep 20, 2023Sep 22, 2023View →
GANX
GAIN THERAPEUTICS, INC.
SALE
Chief Executive Officer
2,5507,650Sep 20, 2023Sep 22, 2023View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASE
Chief Executive Officer
3,3003,300Jul 1, 2023Jul 5, 2023View →
GANX
GAIN THERAPEUTICS, INC.
SALE
Chief Executive Officer
3,3009,900Jul 1, 2023Jul 5, 2023View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
75,00075,000Mar 23, 2023Mar 27, 2023View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
150,000150,000Mar 23, 2023Mar 27, 2023View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
60,90060,900Sep 20, 2022Sep 22, 2022View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
10,20010,200Sep 20, 2022Sep 22, 2022View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
79,20079,200Jul 15, 2022Jul 19, 2022View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,20013,200Jul 15, 2022Jul 19, 2022View →
GANX
GAIN THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
200,000$5.86$1.17M200,000Dec 23, 2021Dec 28, 2021View →
Other insiders · GANX
Loading peer insiders…
About this filer
CIK 0001370820
ROLE
Chief Executive Officer
PRIMARY
GANX
COMPANIES
1
ACTIVE SINCE
Dec 2021
MARKETPEEL · /INSIDER/0001370820DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback